|
Characteristics
|
N
|
Median OS
|
P
|
Median LRPFS
|
P
|
Median PFS
|
P
|
|---|
| | |
Months (95%CI)
| |
Months (95%CI)
| |
Months (95%CI)
| |
|---|
|
GTV
| | | | | | | |
|
GTV
L
|
13
|
16.3 (11.6-21.0)
|
0.005
|
11.0 (2.6-19.4)
|
0.013
|
9.0 (0.8-17.2)
|
0.008
|
|
GTV
G
|
17
|
9.5 (8.0-11.0)
| |
6.0 (4.1-7.9)
| |
4.8 (3.1-6.5)
| |
|
GTV
N
| |
-
| | | | | |
|
< Median
|
15
|
13.2 (8.2-18.2)
|
0.085
|
9.8 (7.3-12.3)
|
0.18
|
8.4 (4.9-11.9)
|
0.086
|
|
≥ Median
|
15
|
9.5 (7.511.5)
| |
6.0 (3.3-8.7)
| |
4.8 (3.2-6.4)
| |
|
Nodal status
| | | | | | | |
|
N0
|
13
|
13.2 (7.8-18.6)
|
0.25
|
9.8 (7.5-12.1)
|
0.36
|
8.4 (5.2-11.6)
|
0.25
|
|
N1
|
17
|
9.8 (7.8-11.8)
| |
6.1 (4.1-8.1)
| |
4.8 (3.1-6.5)
| |
|
Age
| | | | | | | |
|
< Median
|
14
|
10.5 (7.2-13.8)
|
0,99
|
7.6 (6.1-9.1)
|
0.97
|
5.7 (4.6-6.8)
|
0.92
|
|
≥ Median
|
16
|
9.8 (9.0-10.6)
| |
7.8 (2.5-13.1)
| |
5.7 (0.8-10.6)
| |
|
Gender
| | | | | | | |
|
Male
|
21
|
10.3 (9.0-11.6)
|
0.86
|
7.6 (6.3-8.9)
|
0.52
|
5.7 (4.5-6.9)
|
0.89
|
|
Female
|
9
|
10.3 (8.8-11.8)
| |
10.3 (3.0-17.6)
| |
7.3 (2.6-12.0)
| |
|
ECOG
| | | | | | | |
|
0-1
|
23
|
10.3 (9.2-11.4)
|
0.61
|
8.0 (5.7-10.3)
|
0.84
|
5.3 (3.1-7.5)
|
0.88
|
|
2
|
7
|
10.3 (7.7-12.9)
| |
7.6 (6.3-8.9)
| |
7.3 (3.2-11.4)
| |
|
Location of Tumor
| | | | | | | |
|
Head
|
23
|
10.3 (9.1-11.5)
|
0.58
|
7.6 (4.6-10.6)
|
0.52
|
5.7 (4.8-6.6)
|
0.31
|
|
Body
|
7
|
10.5 (8.7-12.3)
| |
8.7 (6.4-11.0)
| |
7.3 (2.2-12.4)
| |
- Abbreviations: ECOG Eastern cooperative oncology group; GTV gross tumor volume; GTV
G
gross tumor volume greater than 91.1 (cm3); GTV
L
gross tumor volume lesser than 91.1 (cm3); GTV
N
nodal gross tumor volume; LRPFS local regional progression-free survival; OS overall survival; PFS progression-free survival
